Literature DB >> 22983691

Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior.

Hakan Akinci1, Aysegul Kapucu, Kadriye Akgun Dar, Ozlem Celik, Banu Tutunculer, Gozde Sirin, Buge Oz, Nurperi Gazioglu, Haluk Ince, Süheyla Aliustaoglu, Pinar Kadioglu.   

Abstract

The aim of the study was to evaluate the presence of aromatase cytochrome P450 enzyme (P450AROM) expression in normal pituitary tissues and tumor tissues of patients with prolactinoma and to examine the impact of the P450AROM expression on clinical outcome. Twenty-six consecutive human pituitary tissue samples were obtained from autopsies performed at the Institute of Forensic Medicine. Sixty-four patients who had an adenomectomy between 2000 and 2009 after prolactinoma diagnosis with histologically confirmed pituitary tumor tissues were retrospectively included in this study. The slices from the pituitary tissues were subjected to immunohistochemical staining for evaluation of P450AROM and estrogen receptor beta (ER beta) subunit. Immunohistochemistry results were compared according to age, gender, remission rate, resistance and invasion status of the patients. Higher than normal P450AROM expression was found in the pituitary tissues of the patients with prolactinoma (p < 0.001). P450AROM intensity had no relation to resistance or remission in patients with prolactinoma (p = 0.44, p = 0.45, respectively). The subgroup analysis showed that compared to males without invasive adenoma, males with invasive adenoma had higher P450AROM expression (p = 0.048). ER beta was found to have an impact on resistance (p = 0.049). This study shows that P450AROM expression is present in the pituitary tissues of patients with prolactinoma and that this presence could be important in development and tumor behavior of prolactinomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22983691     DOI: 10.1007/s11102-012-0436-2

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  31 in total

Review 1.  Pituitary disorders during pregnancy.

Authors:  D Prager; G D Braunstein
Journal:  Endocrinol Metab Clin North Am       Date:  1995-03       Impact factor: 4.741

2.  Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody.

Authors:  K Thapar; K Kovacs; B W Scheithauer; L Stefaneanu; E Horvath; P J Pernicone; D Murray; E R Laws
Journal:  Neurosurgery       Date:  1996-01       Impact factor: 4.654

3.  Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.

Authors:  H Lv; C Li; S Gui; Y Zhang
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

Review 4.  Clinical review: Diagnosis and management of pituitary carcinomas.

Authors:  Gregory A Kaltsas; Panagiotis Nomikos; George Kontogeorgos; Michael Buchfelder; Ashley B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

5.  Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.

Authors:  Wenbin Ma; Hidetoshi Ikeda; Takashi Yoshimoto
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

6.  Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen.

Authors:  J C Prior; T A Cox; D Fairholm; E Kostashuk; R Nugent
Journal:  J Clin Endocrinol Metab       Date:  1987-02       Impact factor: 5.958

7.  Aromatase cytochrome P450 enzyme expression in human pituitary.

Authors:  Pinar Kadioglu; Gokhan Oral; Muge Sayitoglu; Nevin Erensoy; Berna Senel; Nurperi Gazioglu; Aydin Sav; Gursel Cetin; Ugur Ozbek
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.

Authors:  Zhe Bao Wu; Wei Ming Zheng; Zhi Peng Su; Yong Chen; Jin Sen Wu; Cheng De Wang; Chen Lin; Yan Jun Zeng; Qi Chuan Zhuge
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

9.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

10.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.

Authors:  S Detre; G Saclani Jotti; M Dowsett
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

View more
  9 in total

1.  Opposite effects of dihydrotestosterone and estradiol on apoptosis in the anterior pituitary gland from male rats.

Authors:  María Laura Magri; María Florencia Gottardo; Sandra Zárate; Guadalupe Eijo; Jimena Ferraris; Gabriela Jaita; Mariela Moreno Ayala; Marianela Candolfi; Daniel Pisera; Adriana Seilicovich
Journal:  Endocrine       Date:  2015-08-22       Impact factor: 3.633

2.  Localization of the aromatase enzyme expression in the human pituitary gland and its effect on growth hormone, prolactin, and thyroid stimulating hormone axis.

Authors:  Asli Sezgin Caglar; Aysegul Kapucu; Kadriye Akgun Dar; Hande Mefkure Ozkaya; Erkan Caglar; Haluk Ince; Pinar Kadioglu
Journal:  Endocrine       Date:  2015-02-20       Impact factor: 3.633

3.  Immunohistochemical Expression of p16 and p21 in Pituitary Tissue Adjacent to Pituitary Adenoma versus Pituitary Tissue Obtained at Autopsy: Is There a Difference?

Authors:  Emilija Manojlovic Gacic; Milica Skender-Gazibara; Ivan Soldatovic; Dusko Dundjerovic; Novica Boricic; Savo Raicevic; Vera Popovic
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

4.  Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.

Authors:  Hande Mefkure Ozkaya; Nil Comunoglu; Fatma Ela Keskin; Buge Oz; Ozlem Asmaz Haliloglu; Necmettin Tanriover; Nurperi Gazioglu; Pinar Kadioglu
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

Review 5.  Gene expression in prolactinomas: a systematic review.

Authors:  Justin Seltzer; Thomas C Scotton; Keiko Kang; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

6.  Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.

Authors:  Alev Selek; Berrin Cetinarslan; Yesim Gurbuz; Ilhan Tarkun; Zeynep Canturk; Burak Cabuk
Journal:  Endocrine       Date:  2014-10-10       Impact factor: 3.633

7.  Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women.

Authors:  Yin-Xia Su; Guo-Li Du; Hong-Li Shen; Wen Wang; Jian-Ling Bao; Aizezijiang Aierken; Bo-Wei Wang; Sheng Jiang; Jun Zhu; Xiao-Ming Gao
Journal:  J Int Med Res       Date:  2019-06-10       Impact factor: 1.671

8.  Local transformations of androgens into estradiol by aromatase P450 is involved in the regulation of prolactin and the proliferation of pituitary prolactin-positive cells.

Authors:  María José García Barrado; Enrique J Blanco; Marta Carretero Hernández; María Carmen Iglesias Osma; Manuel Carretero; Julio J Herrero; Deborah Jane Burks; José Carretero
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

Review 9.  Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.

Authors:  María José García-Barrado; Enrique J Blanco; María Carmen Iglesias-Osma; Marta Carretero-Hernández; Leonardo Catalano-Iniesta; Virginia Sanchez-Robledo; Manuel Carretero; Julio Joaquín Herrero; Sixto Carrero; José Carretero
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.